MGC Pharmaceuticals Limited (MGCLF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören MGC Pharmaceuticals Limited (MGCLF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 46/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026MGC Pharmaceuticals Limited (MGCLF) Sağlık ve Boru Hattı Genel Bakışı
MGC Pharmaceuticals Limited is an Australian bio-pharma company specializing in the development and supply of phytomedicines, including cannabis-based therapies. With products targeting epilepsy, dementia, and COVID-19, MGC Pharma operates in the evolving medicinal cannabis market, facing regulatory hurdles and competition from established pharmaceutical companies.
Yatırım Tezi
MGC Pharmaceuticals operates in the high-growth medicinal cannabis market, which is expected to continue expanding as regulations evolve and acceptance increases. The company's pipeline, including CimetrA (Phase III for COVID-19), CannEpil (Phase IIb for epilepsy), and CogniCann (Phase II for dementia), represents potential value drivers. However, the company's negative profit margin of -614.6% and reliance on OTC markets present significant risks. Successful completion of clinical trials and regulatory approvals are critical catalysts. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainties inherent in pharmaceutical development.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.01 billion, reflecting its small-cap status.
- Negative P/E ratio of -0.06, indicating current unprofitability.
- Gross margin of 38.0%, suggesting potential for profitability with increased sales and cost management.
- Profit margin of -614.6%, highlighting significant operational losses.
- Beta of 0.97, indicating market-correlated volatility.
Rakipler & Benzerleri
Güçlü Yönler
- Pipeline of product candidates targeting unmet medical needs.
- Proprietary formulations and intellectual property.
- Expertise in phytomedicine development.
- Consulting services providing additional revenue stream.
Zayıflıklar
- Negative profit margins and reliance on external funding.
- Limited commercialization experience.
- Small market capitalization and OTC listing.
- Dependence on regulatory approvals for key products.
Katalizörler
- Upcoming: Completion of Phase III clinical trials for CimetrA for COVID-19.
- Upcoming: Results from Phase IIb clinical trials for CannEpil for drug-resistant epilepsy.
- Upcoming: Data readout from Phase II clinical trials for CogniCann for dementia.
- Ongoing: Regulatory approvals for key product candidates in various markets.
- Ongoing: Expansion of distribution network and strategic partnerships.
Riskler
- Potential: Failure to obtain regulatory approvals for key product candidates.
- Potential: Unsuccessful clinical trial outcomes.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Dependence on external funding and potential dilution.
- Ongoing: Risks associated with operating in the evolving medicinal cannabis market.
Büyüme Fırsatları
- Expansion of CimetrA for COVID-19 treatment: Successful completion of Phase III clinical trials and subsequent regulatory approval for CimetrA could provide a significant revenue stream. The global market for COVID-19 treatments remains substantial, although evolving, presenting a potential opportunity for MGC Pharma to capture market share with an effective symptomatic treatment. Timeline: Regulatory approval within 12-24 months pending trial outcomes.
- Commercialization of CannEpil for drug-resistant epilepsy: CannEpil, a cannabis-based therapy in Phase IIb trials, targets drug-resistant epilepsy, a market with significant unmet needs. Positive trial results and regulatory approval could position CannEpil as a valuable treatment option. The epilepsy therapeutics market is projected to reach billions of dollars, offering substantial growth potential. Timeline: Potential market entry within 2-3 years pending trial success and regulatory approvals.
- Development and launch of CogniCann for dementia: CogniCann, in Phase II clinical trials, aims to provide symptomatic relief for dementia. The global dementia therapeutics market is growing rapidly due to the aging population. Successful development and commercialization of CogniCann could address a significant unmet need and generate substantial revenue. Timeline: Market entry within 3-5 years, contingent on clinical trial outcomes and regulatory pathways.
- Geographic expansion into new markets: MGC Pharmaceuticals can expand its market reach by targeting new geographic regions with favorable regulatory environments for medicinal cannabis. This includes exploring opportunities in Europe, North America, and Asia-Pacific. Strategic partnerships and distribution agreements can facilitate market entry and accelerate revenue growth. Timeline: Ongoing, with specific market entry strategies dependent on regulatory changes and market assessments.
- Strategic partnerships and acquisitions: MGC Pharmaceuticals can pursue strategic partnerships or acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other pharmaceutical companies or biotech firms can accelerate drug development and commercialization efforts. Acquisitions of complementary businesses can provide synergies and enhance overall value. Timeline: Opportunistic, based on available opportunities and strategic fit.
Fırsatlar
- Expansion into new geographic markets.
- Strategic partnerships and acquisitions.
- Increasing acceptance of medicinal cannabis.
- Growing demand for alternative therapies.
Tehditler
- Stringent regulatory requirements and clinical trial risks.
- Competition from established pharmaceutical companies.
- Fluctuations in cannabis prices and market demand.
- Changes in government regulations regarding cannabis use.
Rekabet Avantajları
- Proprietary formulations and intellectual property related to its phytomedicines.
- Clinical trial data and regulatory approvals for its key product candidates.
- Established relationships with healthcare providers and distributors.
- Expertise in the development and manufacturing of cannabis-based therapies.
MGCLF Hakkında
MGC Pharmaceuticals Limited, founded in 2014 and headquartered in West Perth, Australia, is a bio-pharma company focused on developing and supplying phytomedicines globally. Originally named Erin Resources Limited, the company rebranded in December 2015 to reflect its focus on pharmaceutical development. MGC Pharma produces and supplies both medicinal cannabis products and non-cannabis phytomedicines, targeting unmet medical needs. Their key product candidates include CimetrA, currently in Phase III clinical trials for symptomatic treatment of early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant epilepsy; and CogniCann, in Phase II clinical trials for symptomatic relief of dementia. The company also offers the ArtemiC range of products, cannabinoid products, and non-pharma products. In addition to its pharmaceutical development, MGC Pharma provides consulting services, including clinical research support. The company operates in the rapidly evolving medicinal cannabis market, navigating complex regulatory landscapes and seeking to establish itself as a provider of innovative phytomedicines.
Ne Yaparlar
- Develop and supply phytomedicines globally.
- Produce medicinal cannabis products.
- Produce non-cannabis phytomedicines.
- Develop CimetrA for symptomatic treatment of early COVID-19.
- Develop CannEpil for drug-resistant Epilepsy.
- Develop CogniCann for symptomatic relief of Dementia.
- Offer ArtemiC range of products.
- Provide consulting services, including clinical research services.
İş Modeli
- Develop and commercialize proprietary phytomedicines.
- Generate revenue through the sale of medicinal cannabis and non-cannabis products.
- Provide consulting services to other companies in the pharmaceutical and biotech industries.
- Out-license or partner for the commercialization of certain products in specific territories.
Sektör Bağlamı
MGC Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment experiencing growth driven by increasing demand for affordable medicines and innovative therapies. The medicinal cannabis market is a subset of this industry, characterized by evolving regulations and increasing acceptance of cannabis-based treatments. MGC Pharma competes with established pharmaceutical companies and other cannabis-focused biotechs. The industry is subject to stringent regulatory requirements and clinical trial processes, requiring significant investment and expertise.
Kilit Müşteriler
- Patients seeking alternative or complementary treatments.
- Healthcare providers prescribing or recommending phytomedicines.
- Pharmaceutical distributors and retailers.
- Research institutions and clinical trial organizations.
Finansallar
Grafik & Bilgi
MGC Pharmaceuticals Limited (MGCLF) hisse senedi fiyatı: Price data unavailable
Son Haberler
MGCLF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MGCLF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
MGCLF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MGCLF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Roby Reuven Zomer
CEO
Roby Reuven Zomer serves as the Chief Executive Officer of MGC Pharmaceuticals. His background includes experience in the pharmaceutical and biotechnology sectors. He has held various leadership positions, contributing to strategic planning, business development, and operational execution. Zomer's expertise spans across drug development, clinical trials, and commercialization strategies. He brings a wealth of knowledge in navigating the complexities of the pharmaceutical industry and driving growth for innovative healthcare companies.
Sicil: Under Roby Reuven Zomer's leadership, MGC Pharmaceuticals has focused on advancing its clinical pipeline, including CimetrA, CannEpil, and CogniCann, through clinical trials. He has overseen the expansion of the company's product portfolio and the development of strategic partnerships. Key milestones include progressing CimetrA to Phase III clinical trials for COVID-19 and advancing CannEpil and CogniCann through Phase II trials for epilepsy and dementia, respectively.
MGCLF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that MGC Pharmaceuticals may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Increased risk of delisting or trading suspension.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's filings with the SEC or other regulatory agencies.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Development of pharmaceutical products with clinical trials underway.
- Presence of a CEO and management team with relevant experience.
- Intellectual property protection for key products.
- Partnerships with reputable research institutions or healthcare providers.
- Company website and investor relations materials.
MGC Pharmaceuticals Limited Hissesi: Cevaplanan Temel Sorular
MGCLF için değerlendirilmesi gereken temel faktörler nelerdir?
MGC Pharmaceuticals Limited (MGCLF) şu anda yapay zeka skoru 46/100, düşük puanı gösteriyor. Temel güçlü yan: Pipeline of product candidates targeting unmet medical needs.. İzlenmesi gereken birincil risk: Potential: Failure to obtain regulatory approvals for key product candidates.. Bu bir finansal tavsiye değildir.
MGCLF MoonshotScore'u nedir?
MGCLF şu anda MoonshotScore'da 46/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MGCLF verileri ne sıklıkla güncellenir?
MGCLF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MGCLF hakkında ne diyor?
MGCLF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
MGCLF'a yatırım yapmanın riskleri nelerdir?
MGCLF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Failure to obtain regulatory approvals for key product candidates.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MGCLF'ın P/E oranı nedir?
MGCLF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MGCLF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
MGCLF aşırı değerli mi, yoksa düşük değerli mi?
MGC Pharmaceuticals Limited (MGCLF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MGCLF'ın temettü verimi nedir?
MGC Pharmaceuticals Limited (MGCLF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.
- AI analysis pending for MGCLF, which could provide further insights.